Innate lymphoid cells in atherosclerosis

Daniel Engelbertsen; Andrew H Lichtman

doi:10.1016/j.ejphar.2017.04.030

Innate lymphoid cells in atherosclerosis

Eur J Pharmacol. 2017 Dec 5:816:32-36. doi: 10.1016/j.ejphar.2017.04.030. Epub 2017 Apr 25.

Authors

Daniel Engelbertsen¹, Andrew H Lichtman²

Affiliations

¹ Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, 77 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA. Electronic address: daniel.engelbertsen@med.lu.se.
² Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, 77 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA.

PMID: 28449862
DOI: 10.1016/j.ejphar.2017.04.030

Abstract

The family of innate lymphoid cells (ILCs) consisting of NK cells, lymphoid tissue inducer cells and the 'helper'-like ILC subsets ILC1, ILC2 and ILC3 have been shown to have important roles in protection against microbes, regulation of inflammatory diseases and involved in allergic reactions. ILC1s produce IFN-γ upon stimulation with IL-12 and IL-18, ILC2s produce IL-5 and IL-13 responding to IL-33 and IL-25 while ILC3s produce IL-17 and IL-22 after stimulation with IL-23 or IL-1. Although few studies have directly investigated the role for ILCs in atherosclerosis, several studies have investigated transcription factors and cytokines shared by ILCs and T helper cells. In this review we summarize our current understanding of the role of ILC in atherosclerosis and discuss future directions.

Keywords: Atherosclerosis; Cytokines; Inflammation; Innate lymphoid cells; Mouse models.

Publication types

Review

MeSH terms

Animals
Atherosclerosis / immunology*
Humans
Immunity, Innate*
Lymphocytes* / cytology
Lymphocytes* / immunology

Grants and funding

R01 HL087282/HL/NHLBI NIH HHS/United States